Welcome to our dedicated page for AGILE THERAPEUTICS news (Ticker: AGRX), a resource for investors and traders seeking the latest updates and insights on AGILE THERAPEUTICS stock.
Agile Therapeutics Inc. (AGRX) is an innovative women's healthcare company focused on developing non-daily contraceptive solutions through its proprietary transdermal technology. This page serves as the definitive source for verified news and official announcements related to product developments, regulatory milestones, and corporate updates.
Investors and healthcare professionals will find comprehensive coverage of Twirla® contraceptive patch updates, financial performance reports, and strategic partnership announcements. Our curated collection ensures timely access to earnings releases, clinical trial progress, and manufacturing updates while maintaining strict adherence to factual reporting standards.
Key information categories include FDA regulatory communications, research advancements in transdermal drug delivery, and market expansion initiatives. All content is rigorously verified to provide reliable insights into the company's position within the women's health sector.
For those monitoring AGRX's progress in contraceptive innovation, we recommend bookmarking this page and checking regularly for essential updates. Our commitment to neutral, accurate reporting makes this your trusted resource for understanding Agile Therapeutics' role in advancing patient-centric healthcare solutions.
Agile Therapeutics (Nasdaq: AGRX) reported a first-quarter 2022 net revenue of $1.8 million, aligning with its guidance. The company experienced double-digit growth in Twirla demand, with significant increases in total prescriptions, new prescriptions, and prescribers. Operating expenses were $15.8 million, slightly higher than the prior year, but within guidance. Agile plans to lower future expenses and has improved its cash position with recent financing. Notably, the company regained compliance with Nasdaq's bid price requirement after its stock was under scrutiny.
Agile Therapeutics (Nasdaq: AGRX) announced the results of its first-year pharmacovigilance safety surveillance for Twirla®, a transdermal contraceptive system. The FDA-approved product showed consistency with the SECURE trial results, demonstrating no venous thromboembolic events and only two serious adverse events reported during the post-marketing period. Approximately 11,000 women-years of data were collected, and adhesion issues were rare, with only 14 replacements needed. The data highlights Twirla's safety profile in real-world use and supports its continuing acceptance among healthcare providers.
Agile Therapeutics (Nasdaq: AGRX) will release its Q1 2022 financial results on May 12, 2022, after market close. A live conference call and webcast will follow at 4:30 p.m. ET to discuss these results and provide a business update. Investors can dial in using (888) 330-2454 (U.S.) or (240) 789-2714 (international) with conference ID 7871426. The event will also be available for replay via the company's Investor Relations page.
Agile Therapeutics, Inc. (Nasdaq: AGRX) announced a 1-for-40 reverse stock split effective April 26, 2022. This move aims to increase the stock price to comply with Nasdaq's minimum bid requirement. Post-split, approximately 146.7 million shares will reduce to about 3.7 million shares, with adjustments made to stock options and warrants. Stockholders will not need to take action for electronic shares, while those with physical certificates will receive instructions for exchange. The CUSIP number will change as of April 26, 2022.
Agile Therapeutics (Nasdaq: AGRX) reported strong growth in Twirla prescription data for Q1 2022, with a 29% increase in cycles dispensed (16,602) and a 27% rise in total prescriptions (12,494). New prescriptions grew by 22% to 5,351, and refill prescriptions saw a 31% increase to 7,143. The total number of prescribers also rose 26% to 5,837. The company is focusing on initiatives such as the Afaxys partnership and a commercial campaign to sustain this growth momentum throughout 2022.
Agile Therapeutics (Nasdaq: AGRX) announced receiving $4.7 million in net proceeds from the New Jersey Economic Development Authority's Net Operating Loss (NOL) program. This non-dilutive funding will support the company's operations and growth plans for 2022. The NOL program allows NJ-based biotechnology firms to sell net operating losses to profitable corporations, providing a cash influx for growth activities, including R&D.
Agile Therapeutics (Nasdaq: AGRX) announced that data from its first-year postmarketing pharmacovigilance safety surveillance for Twirla (levonorgestrel and ethinyl estradiol) will be presented at the 2022 ACOG Annual Meeting from May 4-6, 2022. The company emphasized its commitment to patient safety and expressed encouragement regarding the first-year safety data. The poster presentation will be available to attendees and online after May 6, 2022. Twirla is a once-weekly contraceptive patch aimed at women with a BMI < 30 kg/m², with specific contraindications outlined.
Agile Therapeutics (AGRX) launched its first consumer commercial for the Twirla birth control patch on March 30, 2022. The ad targets women aged 18-24, aiming to reach 5.7 million viewers in five key states. Unlike traditional advertising, the campaign utilizes CTV for tailored audience engagement. Directed by Maya Albanese, the ad highlights the importance of female relationships and reproductive health choices. The company emphasizes its commitment to transparency and authenticity, aligning with Gen Z's values, while the Twirla patch is designed for women with a BMI < 30.
Agile Therapeutics (Nasdaq: AGRX) reported Q4 2021 results showing significant growth in Twirla demand, with total prescriptions increasing by 33% and total cycles dispensed by 32% compared to Q3 2021. The company is set to launch a new connected TV commercial in April 2022 to further boost demand. Total net revenue for Q4 was $1.5 million, and full-year revenue reached $4.1 million. However, Agile faced a net loss of $23.4 million for Q4 and $74.9 million for the full year, highlighting ongoing financial challenges. The company is focusing on partnerships and targeted markets to enhance growth.
Agile Therapeutics (Nasdaq: AGRX) has completed a registered direct offering, raising approximately $4.85 million through the sale of 2,425 shares of Series A and Series B convertible preferred stock along with warrants to purchase up to 24,250,000 shares of common stock. Each preferred share has a stated value of $1,000 and a conversion price of $0.20 per share. Proceeds will be utilized for working capital and corporate purposes. H.C. Wainwright & Co. served as the exclusive placement agent for the transaction.
FAQ
What is the current stock price of AGILE THERAPEUTICS (AGRX)?
What is the market cap of AGILE THERAPEUTICS (AGRX)?
